drugset / Trial / NCT00687141

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects

NCT00687141 ↗

Phase 1 Completed 112 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The primary purpose of this study is to investigate the safety and tolerability of AZD0328 following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum tolerated dose.

Timeline

Start
2007-11
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD0328 Small molecule — Oral

Indications